Topics
- COVID-19 (101)
- Advertising (74)
- COVID-19 vaccines (62)
- Prescription medicines (29)
- Medical devices (20)
- Regulatory compliance (18)
- Alert/Advisory (14)
- Medicines safety (9)
- In Vitro Diagnostic medical devices (IVDs) (6)
- Manufacturing (6)
- Disinfectants/Sterilants (5)
- Medicines (5)
- OTC medicines (3)
- Labelling and packaging (2)
- Shortages (2)
- Australian Register of Therapeutic Goods (ARTG) (1)
- Biologicals (1)
- Medicinal cannabis hub (1)
- Safety (1)
- Scheduling (1)
- Unapproved therapeutic goods (1)
Collection content
293 result(s) found, displaying 61 to 70
- Media releasesVaxine Pty Ltd fined $13,320 for alleged unlawful advertising of an unapproved COVID-19 vaccineThe TGA has issued an infringement notice for $13,320 to Vaxine Pty Ltd of Adelaide for advertising an unapproved COVID-19 vaccine in alleged breach of the Therapeutic Goods Act 1989.
- COVID-19 vaccine safety reportsCOVID-19 vaccine weekly safety report - 24-03-2022Information about the TGA's safety monitoring of COVID-19 vaccines.
- COVID-19 vaccine safety reportsCOVID-19 vaccine weekly safety report - 17-03-2022Information about the TGA's safety monitoring of COVID-19 vaccines.
- Media releasesTGA approves provisional determination for Biocelect Pty Ltd for COVID-19 vaccine, NuvaxovidTGA, part of the Department of Health, has granted a second provisional determination to Biocelect Pty Ltd (on behalf of Novavax Inc.) in relation to its COVID-19 vaccine, Nuvaxovid.
- Media releasesVictorian company Getafix Café Pty Ltd fined $13,320 for alleged unlawful advertising of COVID-19 Rapid Antigen Test KitThe TGA has issued an infringement notice of $13,320 to Getafix Café Pty Ltd (the company) for an alleged breach of the Therapeutic Goods Act 1989 in relation to the advertising of a COVID-19 rapid antigen test on its website.
- COVID-19 vaccine safety reportsCOVID-19 vaccine weekly safety report - 10-03-2022Information about the TGA's safety monitoring of COVID-19 vaccines.
- Media releasesTGA advice for consumers on purchasing COVID-19 rapid antigen testsThe TGA is urging consumers to only purchase COVID-19 rapid antigen tests (RATs) that are approved for use in Australia to avoid the risk of poor test performance that could arise from using unapproved, repackaged or repurposed RATs.
- Media releasesTGA cautions consumers over counterfeit ivermectinConsumers are advised to be cautious about ivermectin products that are sold by unverified online stores.
- Media releasesHerbal medicine practitioner fined $2,664 for making 'miracle' claimsThe TGA has issued an infringement notice for $2,664 to an individual for a NSW based herbal medicine practitioner for an alleged breach of the Advertising Code.
- Media releasesTGA provisionally approves AstraZeneca's combination therapy (tixagevimab and cilgavimab, EVUSHELD) - for pre-exposure prevention (prophylaxis) of COVID-19The TGA has granted provisional approval to AstraZeneca Pty Ltd for its tixagevimab and cilgavimab (EVUSHELD) for the prevention of COVID-19 in people who are at risk of infection but have not been exposed to the virus, known as pre-exposure prevention of COVID-19.